Epigenetic causes of prostate cancer

September 5, 2012

(Medical Xpress)—In about half of all prostate tumours, there are two genetic areas that are fused with one another. When this is not the case, the exact way cancer cells originate in prostate tumours was not clear until now. Scientists at the Max Planck Institute for Molecular Genetics in Berlin, in cooperation with a team of international researchers, were able to show that the genesis of this fusion-negative prostate cancer has epigenetic causes: methyl groups are distributed differently over the DNA in the cancer cells than in healthy cells. Thanks to this knowledge, physicians may be able to achieve greater specificity in treating prostate tumours in future. In addition, the aberrant DNA methylations can be used as a potential biomarker for identifying prostate cancer.

About half of all cases of prostate cancer originate through fusion of two genetic areas. As a result, the ERG gene is activated in these fusion-positive cells and propagate, leading to tumourigenesis. Fusion-positive prostate cancer can be treated with PARP1 inhibitors that turn off the repair system of the .

However, it has not been clear how prostate tumours without a fused ERG gene acquire their tumourigenic potential. Now, a team of scientists headed by Michal-Ruth Schweiger from the Department of Vertebrate Genomics have investigated the global DNA methylation pattern – i.e. at which locations the DNA possesses methyl groups – in fusion-negative tumours. They have discovered that, compared to fusion-positive tumours, the fusion-negative tumours display more aberrant DNA methylations, which are most likely causative for the malignant transformation of prostate cells.

Moreover, the scientists found large amounts of the enzyme EZH2 in the cells of the tumours. This histone methyltransferase couples histone and DNA methylation and also transfers methyl groups to the DNA. Further functional analyses link EZH2 to the aberrant DNA methylations in negative tumours. As reason for the significantly increased amount of EZH2 the scientists found very low concentrations of miRNA-26a, a micro-RNA that targets EZH2 for degradation.

The researchers think that their findings will further enhance diagnosis and specific treatment options for prostate cancer patients. "Regions with different patterns can be used as biomarkers to diagnose specific subgroups of cancer", says Schweiger. "In addition, new medications for fusion-negative prostate cancer could operate with greater specificity and therefore be more effective." It is likely that other types of cancer are also based on these kinds of pronounced epigenetic modifications.

Explore further: Abnormal gene product associated with prostate cancer generated by unusual mechanism

More information: Börno ST, et al. Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discovery, Published Online First August 28, 2012; doi: 10.1158/2159-8290.CD-12-0041

Related Stories

Abnormal gene product associated with prostate cancer generated by unusual mechanism

June 19, 2012
Researchers have identified a potential new pathway in prostate cancer cells by which cancer-driving gene products can be generated, according to a study published in Cancer Discovery, a journal of the American Association ...

Half of prostate cancers could potentially benefit from new type of cancer drugs, study finds

May 18, 2011
About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study from the University of Michigan Comprehensive Cancer Center finds.

Researchers discover biomarkers for prostate cancer detection, recurrence

May 14, 2012
Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study ...

Investigational agent shows promise in reducing spread of prostate cancer

April 29, 2011
A drug developed to treat Ewing's Sarcoma, a rare childhood cancer, may also help prevent human prostate cancer from spreading, as seen in new lab studies say researchers at Georgetown Lombardi Comprehensive Cancer Center, ...

Recommended for you

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...

Researchers identify epigenetic orchestrator of pancreatic cancer cells

December 11, 2017
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December ...

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.